These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20508384)

  • 41. The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism.
    Stone MD; Hosking DJ; Garcia-Himmelstine C; White DA; Rosenblum D; Worth HG
    Bone; 1993; 14(5):727-35. PubMed ID: 8268047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects.
    Pepe J; Romagnoli E; Nofroni I; Pacitti MT; De Geronimo S; Letizia C; Tonnarini G; Scarpiello A; D'Erasmo E; Minisola S
    Osteoporos Int; 2005 Jul; 16(7):805-12. PubMed ID: 15551058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.
    Brown AJ; Ritter CS; Knutson JC; Strugnell SA
    Nephrol Dial Transplant; 2006 Mar; 21(3):644-50. PubMed ID: 16221703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transient pseudohypoparathyroidism of the neonate.
    Minagawa M; Yasuda T; Kobayashi Y; Niimi H
    Eur J Endocrinol; 1995 Aug; 133(2):151-5. PubMed ID: 7655638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heterogeneity of pseudohypoparathyroidism type I from the aspect of urinary excretion of calcium and serum levels of parathyroid hormone.
    Mizunashi K; Furukawa Y; Sohn HE; Miura R; Yumita S; Yoshinaga K
    Calcif Tissue Int; 1990 Apr; 46(4):227-32. PubMed ID: 2108792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib.
    Fukumoto S; Suzawa M; Takeuchi Y; Kodama Y; Nakayama K; Ogata E; Matsumoto T; Fujita T
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2554-8. PubMed ID: 8675577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pseudohypoparathyroidism: a rare but important cause of hypocalcaemia.
    Chong PL; Meeking DR
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23345494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
    Kihara T; Ichikawa H; Morimoto H; Yano A; Akagi S; Nakao K; Kohmoto H; Wada J; Kumagai I; Makino H
    Nephron Clin Pract; 2004; 98(3):c93-100. PubMed ID: 15528944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of parathyroid hormone on 1,25-dihydroxyvitamin D formation in type I pseudohypoparathyroidism.
    Aksnes L; Aarskog D
    J Clin Endocrinol Metab; 1980 Dec; 51(6):1223-6. PubMed ID: 6255001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
    Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
    J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3.
    Theiler R; Bischoff H; Tyndall A; Stähelin HB
    Int J Vitam Nutr Res; 1998; 68(1):36-41. PubMed ID: 9503046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of endogenous and exogenous parathyroid hormone on tubular reabsorption of calcium in pseudohypoparathyroidism.
    Yamamoto M; Takuwa Y; Masuko S; Ogata E
    J Clin Endocrinol Metab; 1988 Mar; 66(3):618-25. PubMed ID: 2832440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple pre- and postreceptor defects in pseudohypoparathyroidism (a multicenter study with twenty four patients).
    Radeke HH; Auf'mkolk B; Jüppner H; Krohn HP; Keck E; Hesch RD
    J Clin Endocrinol Metab; 1986 Feb; 62(2):393-402. PubMed ID: 3001127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A patient with extensive cerebral calcification due to pseudohypoparathyroidism: a case report.
    De Silva SW; De Silva SDN; De Silva CE
    BMC Endocr Disord; 2019 Dec; 19(1):142. PubMed ID: 31856822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of circulating immunoreactive components of parathyroid hormone in normal subjects and in patients with primary and secondary hyperparathyroidism: the role of the kidney and of the serum calcium concentration.
    Dambacher MA; Fischer JA; Hunziker WH; Born W; Moran J; Roth HR; Delvin EE; Glorieux FH
    Clin Sci (Lond); 1979 Nov; 57(5):435-43. PubMed ID: 519952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoassays for the detection of parathyroid hormone.
    Jüppner H; Potts JT
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N81-6. PubMed ID: 12412782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A 63-year-old patient with worsening general condition, bone demineralization, hypocalcemia and excess parathyroid hormone: late manifestations of pseudohypohyperparathyroidism].
    Pickenpack A; Lang B; Palitzsch KD; Schölmerich J; Straub RH
    Dtsch Med Wochenschr; 1999 May; 124(18):551-5. PubMed ID: 10356581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effects of calcitriol and parathyroid hormone on serum aluminum in vitamin D-depleted rabbits fed an aluminum-supplemented diet.
    Long JF; Nagode LA; Steinmeyer CL; Renkes G
    Res Commun Chem Pathol Pharmacol; 1994 Jan; 83(1):3-14. PubMed ID: 8165367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.